4
MARKET OVERVIEW
Summarizes the competitive environment, macro signals, and segment-level movements driving market outcomes.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN EUROPE BIOMARKERS MARKET
5.5.1
AVERAGE SELLING PRICE TREND OF BIOMARKERS, BY PRODUCT, 2022-2024
5.5.2
AVERAGE SELLING PRICE OF BIOMARKERS, BY COUNTRY,
5.6.1
IMPORT SCENARIO FOR HS CODE 382200
5.6.2
EXPORT SCENARIO FOR HS CODE 382200
5.7
KEY CONFERENCES AND EVENTS, 2025–2026
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFF ON EUROPE BIOMARKERS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES
5.11.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.3
IN SITU HYBRIDIZATION
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
ADJACENT TECHNOLOGIES
6.3.1
ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)
6.3.1
SENSORS (WEARABLE DEVICES)
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON EUROPE BIOMARKERS MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
CASE STUDIES OF AI IMPLEMENTATION
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
COMPARATIVE ASSESSMENT OF KEY PRODUCTS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
9.2.2
REAGENTS & CHEMICALS
10
EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
COMPARATIVE ASSESSMENT OF KEY TYPES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
10.3.1
PREDICTIVE BIOMARKERS
10.3.2
SURROGATE BIOMARKERS
10.3.3
PHARMACODYNAMICS BIOMARKERS
10.3.4
PROGNOSTIC BIOMARKERS
10.4
VALIDATION BIOMARKER
11
EUROPE BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
APPLICATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS PHARMACEUTICAL FILTRATION ADOPTION IN DIVERSE INDUSTRIES
12
EUROPE BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
12.3.1
PROTEIN MICROARRAY
13
EUROPEAN BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
13.4
IMMUNOLOGICAL DISORDERS
13.5
NEUROLOGICAL DISORDERS
13.6
CARDIOVASCULAR DISORDERS
13.7
OTHER DISEASE INDICATION
14
EUROPEAN BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
14.2
CLINICAL DIAGNOSTICS
14.3
DRUG DISCOVERY & DEVELOPMENT
14.4
PERSONALIZED MEDICINE
15
EUROPE BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS AND MARKET POTENTIAL ACROSS EACH END-USE INDUSTRY
15.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.3
HOSPITALS & DIAGNOSTIC LABORATORIES
15.4
ACADEMIC & RESEARCH INSTITUTES
16
EUROPE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY GEOGRAPHIES AND COUNTRIES
16.2.6
MACROECONOMIC OUTLOOK OF EUROPE
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
17.2
KEY PLAYERS STRATEGY/ RIGHT TO WIN
17.3
REVENUE ANALYSIS, 2022-2024
17.4
MARKET SHARE ANALYSIS,
17.5
COMPANY EVALUATION MATRIX: KEY PLAYERS
17.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
17.5.5.1
COMPANY FOOTPRINT
17.5.5.2
REGION FOOTPRINT
17.5.5.3
PRODUCT FOOTPRINT
17.5.5.4
STERILITY TYPE FOOTPRINT
17.5.5.5
APPLICATION FOOTPRINT
17.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
17.6.1
PROGRESSIVE COMPANIES
17.6.2
RESPONSIVE COMPANIES
17.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
17.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
17.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
17.7
COMPETITIVE SCENARIO
17.7.3
OTHER DEVELOPMENTS
17.8
BRAND/ PRODUCT COMPARISON
17.9
COMPANY VALUATION AND FINANCIAL METRICS
18.1.1
F. HOFFMANN-LA ROCHE LTD.
18.1.4
EUROFINS SCIENTIFIC
18.1.7
SYNEXA LIFE SCIENCES BV
19.1.1.1
KEY SOURCES OF SECONDARY DATA
19.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
19.1.2.1
BREAKDOWN OF PRIMARY INTERVIEWS
19.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
19.2
MARKET SIZE ESTIMATION
19.2.1
EUROPE BIOMARKERS MARKET SIZE ESTIMATION
19.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
19.2.1.2
MNM REPOSITORY ANALYSIS
19.2.1.3
SECONDARY ANALYSIS
19.2.1.4
PRIMARY RESEARCH
19.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
19.3
MARKET GROWTH RATE PROJECTIONS
19.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
20.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Europe Biomarkers Market